reports
Spring Bank Pharmaceuticals Stockholders Approve Combination with F-st...
Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 20, 2020 HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stockholders held earlier today, Spring Bank’s stockholders approved the issuance of shares of Spring Bank common stock to holders of share capital of F-star Therapeutics Li...
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent V...
Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced that its board of directors intends, subject to the receipt of stockholder approval of the Exchange (as defined below) and the reverse stock split, to declare a one-time special dividend on each outstanding share of Spring Bank’s common stock, payable on a post-reve...
Spring Bank Announces Poster Presentation at the 2020 Society for Immu...
Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced an upcoming trial-in-progress poster presentation for SB 11285 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020. SB 11285 is Spring Bank’s intravenously (IV)-administered S...
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and ...
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to additional monotherapy and combination dosing cohorts Abstracts for IV SB 11285 accepted by major oncology scientific conferences for presentation in Q3 and Q4 2020 HOPKINTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical comp...
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine t...
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programsCombined company expected to have at least $40 million in cash prior to closing Spring Bank stockholders to receive two separate contingent value rights related to Spring Bank’s STING agonist and STING antagonist programsCompanies to host joint conference call on July 30, 2020 at 7:30 a.m. Eastern Time HOPKINTON, Mass. and CAMBRIDGE, Uni...
Spring Bank Advances IV SB 11285 Clinical Program
Spring Bank Advances IV SB 11285 Clinical Program - Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) - Clinical Poster for IV SB 11285 Phase 1a/1b trial presented at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting HOPKINTON, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing...
Spring Bank to Present at the Jefferies Virtual Global Healthcare Conf...
Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be participating in the Jefferies Virtual Global Healthcare Conference, taking place June 2-4, 2020. Martin Driscoll, Spring Bank’s President and CEO, will be providing a corporate presentation on June 2, 2020 from 4:00pm to 4:25pm ...
Spring Bank Announces Poster Presentation at the 2020 American Society...
Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting HOPKINTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology (ASCO) Annual Meeti...
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and O...
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I and STING agonists portfolio as potential therapeutics and/or vaccine adjuvants for COVID-19 HOPKINTON, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and...
Spring Bank Provides Update on Business Operations & Clinical Program ...
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohortClinical abstracts for IV SB 11285 Phase 1a/1b trial accepted for presentation at ASCO and 7th ImmunoTherapy of Cancer Conferences HOPKINTON, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage b...
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in C...
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 ...
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year ...
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth quarter and year-ended December 31, 2019 and provided an update on recent corporate and clinical development highlights. “In January, we made the difficult decision to discontinue our development efforts in the fie...
Spring Bank Discontinues Development of Inarigivir for the Treatment o...
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost structure to fund operations into late 2022 HOPKINTON, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has discontinued develo...
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that the company has stopped dosing and enrolling patients in its Phase 2b CATALYST trials, which are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus (HBV). In addition, the company has stopped dosing and enro...
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucle...
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019 HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus (HBV) poster presentations at HepDART 2019 being held December 8 - 12, 2019 in Kauai, Hawaii. “We are excited to present impressive data on our chimeric antisense oligonucleotide (C...
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of ...
Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285 HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initiated dosing patients in a Phase 1 trial of SB 11285, the company’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist. The Phase 1 trial aims to evaluate safety, tolera...
Spring Bank Announces Investor Conference Presentations for the Remain...
Spring Bank Announces Investor Conference Presentations for the Remainder of 2019 HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, chief executive officer, will present at the following investor conferences: Jefferies 2019 London Healthcare Conference: Thursday, November 21, 2019 at 11:20 AM GMT / 5:20 AM ESTPiper Jaffray 31st Annual Healthcare C...
Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and O...
Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update Company to host conference call on Monday, November 11, 2019 at 4:30pm EST to discuss current HBV landscape and update on the company’s development programs HOPKINTON, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial results for the third quarter ...
Spring Bank Announces Interim Top-Line Results from the First Cohort o...
Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients 7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg co-administered with Vemlidy is ongoing HOPKINTON, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treat...
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare...
Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll, President and Chief Executive Officer, and Jonathan Freve, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings with investors at the 2019 Cantor Fitzgerald Global ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.